Royalty Report: Drugs, Disease, Cancer – Collection: 245930

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Disease
  • Cancer
  • Therapeutic
  • HIV / AIDs
  • Immune
  • Antibody
  • Diagnostic
  • Delivery
  • Autoimmune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 245930

License Grant
Licensor grants an exclusive license and/or sublicenses under the Patents, restricted to the Field, to make and have made, to use, to offer for sale, to sell and have sold, to import and have imported, and to export and have exported, the Products in the Territory.
License Property
The patents include Immunotherapy involving stimmulation of THCD28 lymphokins production, and, Immunotherapy involving CD28 stimulation, and, Methods for selectively stimulating proliferation ofT cells, and other related patents.

The Product means any product developed by or on behalf Licensee, the manufacture, use or sale of which is covered by a Valid Claim of the Patents in the country of manufacture, use or sale.

Service means any service provided by Licensee in connection with a Product in the Field.

Field of Use
The Field means ex vivo activation or expansion of human T -cells, including T-cells modified through gene transfer, for treatment and/or prevention of infectious diseases, including, without limitation, AIDS, cancer and immunodeficiency states.

IPSCIO Record ID: 275802

License Grant
Licensor hereby grants to the German Licensee, an exclusive (even as to Licensor), transferable, royalty-bearing license under the Xcellerateâ„¢ Technology, with the right to sublicense as permitted, to research, develop, make, have made, use, import, sell and offer for sale Products in the Field in the Territory.
License Property
Product means any and all products where the manufacture, sale or use of such products would (i) in the absence of the licenses granted in this Agreement infringe at least one Valid Patent Claim of the Licensor Patents in the Territory, or (2) use the Licensor Know-How.

Xcellerateâ„¢ Technology means the Licensor Patents and Licensor Know-How.

Licensor Patents means, to the extent owned or Controlled by Licensor, or owned or Controlled jointly by Licensor and Licensee:
6,352,694 – Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
5,858,358 – Methods for selectively stimulating proliferation of T cells
5,883,223 – CD9 antigen peptides and antibodies thereto

Licensor Know-How means any and all technical information, processes, formulae, data, engineering, inventions, chemical compounds, know-how and trade secrets owned or Controlled by Licensor that relate to the Xcellerated T Cellsâ„¢, Xcellerateâ„¢ II Process and the Xcellerateâ„¢ III Process and any other proprietary information.

Xcellerated T Cells™” means the T cells that are produced by the use of the Xcellerate™ Technology, including but not limited to the use of the Licensor Dynabeads®, Xcellerate™ II Process or Xcellerate™ III Process or derivatives thereof.

Xcellerate™ II Process” means a static process configuration as it exists as of the Effective Date and is defined in Xcyte Therapies Master Production Records MPR 11-0002 & 11-0005 submitted to FDA on September 19, 2001.

Xcellerateâ„¢ III Process means the process configuration based on the WaveBioreactor as it exists as of the Effective Date and is defined in Licensor Therapies Master Production Records MPR 11-0006 & 11-0007 submitted to the FDA on May 15, 2003.

Licensor Dynabeads®” means XR-CD3 and XR-CD28 antibodies produced at Lonza Biologics that are conjugated to super-paramagnetic Dynaspheres MS-4.5-REK particles at Dynal Biotech A.S.A.

Field of Use
Field means any and all HIV retroviral gene therapy applications for human or animal use; provided that use of the technology sublicensed under the Licensor In-Licenses shall be further limited to the Field defined in the respective Licensee In-Licenses, as applicable.

IPSCIO Record ID: 246212

License Grant
The Licensor, owned by Licensee's President and a member of the Board of Directors, grants the Licensee an exclusive, worldwide, sub-licensable, royalty-bearing license to the Patent Rights in the Field, including the right to use, market, distribute, make, have made, sell, have sold, offer to sell, import and export Licensed Products and Licensed Services. entitled “In vivo activation of natural killer cells' and to the patents and patent applications. NK cells provide rapid responses to viral-infected cells, and respond to tumor formation.
License Property
Licensor is the owner by assignment of all legal right, title, and interest in the invention entitled  â€œIn vivo activation of natural killer cells'.

Property No. 62/219,652 IN VIVO ACTIVATION OF NATURAL KILLER CELLS

Field of Use
The term “Field” or “Field of Use” shall mean all applications of the Patent Rights.  Licensee wishes to acquire the Patent Rights to make, use, sell, offer for sale, and import products, methods, and services.

Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.

IPSCIO Record ID: 243435

License Grant
The University grants an exclusive worldwide license under the patent rights and know-how to make, have made, use, import, offer to sell, sell, offer to provide and provide Licensed Products. Such license is worldwide.  The University grants an exclusive option to obtain an exclusive, worldwide license to all new optioned inventions.
License Property
The property is referred to as Licensors 1101 Invention or the 1215 Invention.  The patented invention relates to Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA.  The inventions are detailed in patent applications #08/517,373, #08/700,035, #96/13,457 and also #08/640,444, and continuation applications.
Field of Use
The field shall mean all uses of the know-how and patent rights, cell lines, substances and material produced by cell lines and included in Patent Rights, specifically including, without limitation, research and development, diagnosis, prevention, therapy, and monitoring of all human and animal diseases or disorders, including  autoimmune diseases or disorders, infectious diseases or cancer in humans or animals.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.